| Allan Raskin, MD | |
|
211 Park St, Attleboro, MA 02703-3143 | |
| (508) 236-7020 | |
| (508) 236-7019 |
| Full Name | Allan Raskin |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 42 Years |
| Location | 211 Park St, Attleboro, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871695833 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD06279 (Rhode Island) | Secondary |
| 207P00000X | Emergency Medicine | 54594 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sturdy Memorial Hospital | Attleboro, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sturdy Memorial Hospital Inc | 4981653789 | 42 |
News Archive
A gene that is responsible for cancer growth plays a totally unexpected role in prostate cancer. The gene Stat3 is controlled by the immune modulator interleukin 6 and normally supports the growth of cancer cells. The international research team led by Prof. Lukas Kenner from the Medical University of Vienna, the Veterinary University of Vienna, and the Ludwig Boltzmann Institiute for Cancer Research (LBI-CR) discovered a missing link for an essential role of Stat3 and IL-6 signalling in prostate cancer progression.
Diabetes is a global health concern expected to affect 693 million people worldwide by 2045. It's been well documented how diet and exercise influence risk of type 2 diabetes; however, a new study suggests that early menarche also is associated with a higher risk, but body mass index may mediate this association.
Acurian, a leader in clinical trial patient recruitment and retention, announced today that its opted-in patient database is an effective resource for reaching minority populations for patient recruitment. Increasing minority participation is crucial for trial success and regulatory approval, especially for therapies intended to treat diseases with high incidence and prevalence rates among minorities.
Caution has been urged in the use of blood pressure lowering treatment for heart disease patients after a study in more than 22 000 patients with coronary artery disease found that too low blood pressure was associated with worse outcomes. The analysis from the CLARIFY registry is presented today at ESC Congress and published in The Lancet.
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the second quarter of 2010.
› Verified 7 days ago
| Entity Name | Sturdy Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730106162 PECOS PAC ID: 4981653789 Enrollment ID: O20050119000678 |
News Archive
A gene that is responsible for cancer growth plays a totally unexpected role in prostate cancer. The gene Stat3 is controlled by the immune modulator interleukin 6 and normally supports the growth of cancer cells. The international research team led by Prof. Lukas Kenner from the Medical University of Vienna, the Veterinary University of Vienna, and the Ludwig Boltzmann Institiute for Cancer Research (LBI-CR) discovered a missing link for an essential role of Stat3 and IL-6 signalling in prostate cancer progression.
Diabetes is a global health concern expected to affect 693 million people worldwide by 2045. It's been well documented how diet and exercise influence risk of type 2 diabetes; however, a new study suggests that early menarche also is associated with a higher risk, but body mass index may mediate this association.
Acurian, a leader in clinical trial patient recruitment and retention, announced today that its opted-in patient database is an effective resource for reaching minority populations for patient recruitment. Increasing minority participation is crucial for trial success and regulatory approval, especially for therapies intended to treat diseases with high incidence and prevalence rates among minorities.
Caution has been urged in the use of blood pressure lowering treatment for heart disease patients after a study in more than 22 000 patients with coronary artery disease found that too low blood pressure was associated with worse outcomes. The analysis from the CLARIFY registry is presented today at ESC Congress and published in The Lancet.
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the second quarter of 2010.
› Verified 7 days ago
| Entity Name | Vk New England Management Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114263449 PECOS PAC ID: 7810134640 Enrollment ID: O20130514000605 |
News Archive
A gene that is responsible for cancer growth plays a totally unexpected role in prostate cancer. The gene Stat3 is controlled by the immune modulator interleukin 6 and normally supports the growth of cancer cells. The international research team led by Prof. Lukas Kenner from the Medical University of Vienna, the Veterinary University of Vienna, and the Ludwig Boltzmann Institiute for Cancer Research (LBI-CR) discovered a missing link for an essential role of Stat3 and IL-6 signalling in prostate cancer progression.
Diabetes is a global health concern expected to affect 693 million people worldwide by 2045. It's been well documented how diet and exercise influence risk of type 2 diabetes; however, a new study suggests that early menarche also is associated with a higher risk, but body mass index may mediate this association.
Acurian, a leader in clinical trial patient recruitment and retention, announced today that its opted-in patient database is an effective resource for reaching minority populations for patient recruitment. Increasing minority participation is crucial for trial success and regulatory approval, especially for therapies intended to treat diseases with high incidence and prevalence rates among minorities.
Caution has been urged in the use of blood pressure lowering treatment for heart disease patients after a study in more than 22 000 patients with coronary artery disease found that too low blood pressure was associated with worse outcomes. The analysis from the CLARIFY registry is presented today at ESC Congress and published in The Lancet.
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the second quarter of 2010.
› Verified 7 days ago
| Entity Name | Seahorse Behavioral Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255984902 PECOS PAC ID: 2860721685 Enrollment ID: O20190904001361 |
News Archive
A gene that is responsible for cancer growth plays a totally unexpected role in prostate cancer. The gene Stat3 is controlled by the immune modulator interleukin 6 and normally supports the growth of cancer cells. The international research team led by Prof. Lukas Kenner from the Medical University of Vienna, the Veterinary University of Vienna, and the Ludwig Boltzmann Institiute for Cancer Research (LBI-CR) discovered a missing link for an essential role of Stat3 and IL-6 signalling in prostate cancer progression.
Diabetes is a global health concern expected to affect 693 million people worldwide by 2045. It's been well documented how diet and exercise influence risk of type 2 diabetes; however, a new study suggests that early menarche also is associated with a higher risk, but body mass index may mediate this association.
Acurian, a leader in clinical trial patient recruitment and retention, announced today that its opted-in patient database is an effective resource for reaching minority populations for patient recruitment. Increasing minority participation is crucial for trial success and regulatory approval, especially for therapies intended to treat diseases with high incidence and prevalence rates among minorities.
Caution has been urged in the use of blood pressure lowering treatment for heart disease patients after a study in more than 22 000 patients with coronary artery disease found that too low blood pressure was associated with worse outcomes. The analysis from the CLARIFY registry is presented today at ESC Congress and published in The Lancet.
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the second quarter of 2010.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Allan Raskin, MD 51 Westford Rd, Providence, RI 02906-4942 Ph: (401) 274-0091 | Allan Raskin, MD 211 Park St, Attleboro, MA 02703-3143 Ph: (508) 236-7020 |
News Archive
A gene that is responsible for cancer growth plays a totally unexpected role in prostate cancer. The gene Stat3 is controlled by the immune modulator interleukin 6 and normally supports the growth of cancer cells. The international research team led by Prof. Lukas Kenner from the Medical University of Vienna, the Veterinary University of Vienna, and the Ludwig Boltzmann Institiute for Cancer Research (LBI-CR) discovered a missing link for an essential role of Stat3 and IL-6 signalling in prostate cancer progression.
Diabetes is a global health concern expected to affect 693 million people worldwide by 2045. It's been well documented how diet and exercise influence risk of type 2 diabetes; however, a new study suggests that early menarche also is associated with a higher risk, but body mass index may mediate this association.
Acurian, a leader in clinical trial patient recruitment and retention, announced today that its opted-in patient database is an effective resource for reaching minority populations for patient recruitment. Increasing minority participation is crucial for trial success and regulatory approval, especially for therapies intended to treat diseases with high incidence and prevalence rates among minorities.
Caution has been urged in the use of blood pressure lowering treatment for heart disease patients after a study in more than 22 000 patients with coronary artery disease found that too low blood pressure was associated with worse outcomes. The analysis from the CLARIFY registry is presented today at ESC Congress and published in The Lancet.
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the second quarter of 2010.
› Verified 7 days ago
Hung Q Nguyen, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 211 Park St, Attleboro, MA 02703 Phone: 508-236-7020 | |
Dr. Mark M Mcguire, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: Sturdy Memorial Hospital, 211 Park St., Attleboro, MA 02703 Phone: 508-236-7020 | |
Ronald Van Ness-otunnu, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 211 Park St, Attleboro, MA 02703 Phone: 508-222-5200 | |
Dr. Michael Demelis, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 211 Park Street, Attleboro, MA 02703 Phone: 508-236-7020 | |
Dr. William Thomas Bennett, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 211 Park St, Attleboro, MA 02703 Phone: 508-222-5200 Fax: 508-236-7043 | |
Dr. Brian Bhupendra Patel, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 211 Park St, Attleboro, MA 02703 Phone: 508-236-7040 | |
Dr. Brian J Kelly, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 211 Park St, Attleboro, MA 02703 Phone: 508-236-7046 |